

July 28, 2020  
SymBio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer  
(Securities Code: 4582)

**Onconova Therapeutics Submits Application for Rigosertib to Participate in Federally Funded Human Studies in COVID-19 Disease**

TOKYO, Japan, July 28, 2020 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio") today announced that its U.S. licensor of rigosertib, Onconova Therapeutics, Inc. (Headquarters: Newtown, PA, "Onconova"), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), announced on July 27, 2020 (EST) that it has submitted an application with the National Institute of Allergy and Infectious Disease (NIAID), with the goal of obtaining funding from the National Institutes of Health (NIH) to conduct human studies with rigosertib in COVID-19 disease patients.

According to Onconova's press release, recent preclinical studies conducted with rigosertib demonstrate impressive inhibition of SARS-CoV-2 replication. Onconova also stated that, as an oncology-focused company, Onconova does not currently intend to pursue clinical development in COVID-19 without additional sources of non-dilutive funding.

For Onconova's full press release, please visit Onconova's website:

<https://investor.onconova.com/press-releases>

SymBio does not expect any impact on SymBio's financial outlook for the fiscal year ending December 2020.

### **About Rigosertib**

Rigosertib is a small molecule inhibitor that has a new mechanism of action: it inhibits the activation of RAS as an oncogene-related product, thereby blocking the action of multikinases, including PI3K, and inhibits cellular signaling in cancer cells necessary for their survival and proliferation, thus killing cancer cells. SymBio obtained the development and commercialization licensing rights for Rigosertib from Onconova in July, 2011 for Japan and Korea.

### **About Onconova Therapeutics, Inc.**

Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel drugs to treat cancer, with an initial focus on myelodysplastic syndromes (MDS). Onconova has a pipeline of proprietary targeted agents designed to work against specific cellular pathways that are important in cancer cells. For more information, please visit <https://www.onconova.com>.

### **About SymBio Pharmaceuticals Limited**

SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May 2016, the Company incorporated its wholly-owned subsidiary in the U.S., SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). The Company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs.